Literature DB >> 8252717

Effect of thyroid function on concentrations of lipoprotein(a)

H Engler1, W F Riesen.   

Abstract

The effect of thyroid hormones on concentrations of lipoprotein(a) [Lp(a)] was analyzed in 60 patients with active thyroid dysfunction (hyperthyroidism 30 cases, hypothyroidism 32 cases, and 2 cases with opposite changes) and after normalization of the thyroid state. Treatment of hyperthyroidism increased the mean Lp(a) concentrations by 60% (from 73 to 102 mg/L, P < 0.002); at the same time, low-density lipoprotein cholesterol (LDL-C) increased by 53% (from 2.6 to 3.7 mmol/L, P < 0.0001) and apolipoprotein B (apo B) by 35% (from 0.91 to 1.17 g/L, P < 0.0005). In hypothyroidism, the opposite changes were observed: mean Lp(a) decreased from 136 to 114 mg/L (10%, P < 0.02), LDL-C from 4.6 to 3.9 mmol/L (13%, P < 0.01), and apo B from 1.51 to 1.20 g/L (14%, P < 0.01). Although the changes in Lp(a) concentrations did correlate with changes of LDL-C during treatment of hyperthyroidism (r = 0.43, P < 0.05), and with changes in apo B during thyroxine-substitution therapy for hypothyroidism (r = 0.46, P < 0.05), we observed no associations between Lp(a) and LDL-C or apo B in the euthyroid state. These data cannot rule out the possibility that the thyroid hormone-induced increase in LDL-C receptor activity was responsible for the decreased concentrations of Lp(a) in hyperthyroidism. Given that LDL-C is approximately 30% of the Lp(a) molecule but the changes in Lp(a) concentrations are comparable with those in LDL-C (60% vs 53%), and given that Lp(a) is metabolized by an LDL-C-receptor-independent pathway, the present data suggest a direct effect of thyroid hormones on Lp(a) synthesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252717

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 2.  Lipoprotein (a) and stroke.

Authors:  H J Milionis; A F Winder; D P Mikhailidis
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

3.  The relationship between serum lipoprotein (a) levels and ischemic stroke risk: a cohort study in the Chinese population.

Authors:  Shao-yi Li; Yun Gao; Wei-ning Ma; Hua-chao Wang; Gang Zhou; Wen-chang Guo; Yun-hui Liu
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

4.  Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability.

Authors:  Gary J Grover; Karin Mellström; Liu Ye; Johan Malm; Yi-Lin Li; Lars-Göran Bladh; Paul G Sleph; Mark A Smith; Rocco George; Björn Vennström; Kasim Mookhtiar; Ryan Horvath; Jessica Speelman; Donald Egan; John D Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-29       Impact factor: 11.205

5.  Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients.

Authors:  X Guang-Da; S Hui-Ling; C Zhi-Song; Z Lin-Shuang
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

6.  Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients.

Authors:  Ramachandran Kaliaperumal; Ebenezer William; Thangapaneer Selvam; Shyam M Krishnan
Journal:  J Clin Diagn Res       Date:  2014-02-03

7.  Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism.

Authors:  I C Klausen; L Hegedüs; P S Hansen; F E Nielsen; L U Gerdes; O Faergeman
Journal:  J Mol Med (Berl)       Date:  1995-01       Impact factor: 4.599

8.  Changes of Certain Metabolic and Cardiovascular Markers Fructosamine, H-FABP and Lipoprotein (a) in Patients with Hypothyroidism.

Authors:  Ahmed Naseer Kaftan; Farah H Naser; Muslim A Enaya
Journal:  Med Arch       Date:  2021-02

9.  NMR-based metabolomics to select a surgical method for treating papillary thyroid carcinoma.

Authors:  Bo Wang; Li-Yong Zhang; Si-Si Wang; Ying-Hong Yang; Wen-Xin Zhao
Journal:  Clinics (Sao Paulo)       Date:  2018-11-14       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.